检索结果-南通市图书馆

Pretreatment inflammatory indices predict Bevacizumab response in recurrent Glioma

Cancer Drug Resistance 2020年第3期3卷 623-635页

作者： Alicia Martínez-González Raquel Cabrera marta lloret Pedro C.Lara Department de Matemáticas Universidad de Castilla-La ManchaETSI IndustrialesAvdaCiudad Real 13071Spain. Oncología Radioterápica Hospital Universitario de Gran Canaria Dr Negrin Barranco de la Ballena s/nLas Palmas de Gran CanariaLas Palmas 35010Spain. Facultad de Ciencias de la Salud Universidad de Las Palmas de Gran CanariaPaseo de Blas Cabrera Felipes/nLas Palmas de Gran CanariaLas Palmas 35016Spain. Fundación Canaria del Instituto Canario de Investigación del Cáncer Avda de la Trinidad 61 Torre Agustín Arevalo 7 planta La LagunaSanta Cruz de Tenerife 38204Spain. San Roque University Hospitals Dolores de la Rocha5Las Palmas de Gran CanariaLas Palmas 35001Spain. Fernando Pessoa Canarias University Dolores dela Rocha 14Las Palmas de Gran CanariaLas Palmas 35016Spain.

Aim:It remains unclear what the best therapeutic option for recurrent glioma patients after Stupp treatment ***(BVZ)is commonly administered in progression,but it appears that only some patients *** would be useful to find biomarkers that determine beforehand who these patients ***:The protocol included 31 high-risk progressing glioma patients after Stupp treatment who received BVZ 5-10 mg/kg every 14 days and temozolomide(3-19 cycles,150-200 mg five days each 28-day cycle)during a mean of eight cycles of BVZ or until tumor progression or unacceptable *** analyzed the clinical outcome values of inflammatory indices measured before BVZ ***:Lymphocyte level before BVZ administration was the best independent predictor of overall survival(HR=0.34;95%CI:0.145-0.81;P=0.015).The area under the receiver operating characteristic(ROC)curve was 0.823,with 1.645 being the optimal cut-off value,and 0.80 and 0.85 the sensitivity and specificity values,*** and non-responder survival curves were also significantly different,considering the first and second tertiles as cut-off *** number of BVZ cycles was not related to *** neutrophil platelet levels,platelet-to-lymphocyte ratio(PLR),and neutrophil-to-lymphocyte ratio(NLR)did not have independent predictive *** variables were not correlated with each ***,patients with high NLR and PLR simultaneously(double positive PLR-NLR)showed a worse clinical outcome than the rest(P=0.043).Conclusion:Pretreatment lymphocyte levels and double positive PLR-NLR could be used as non-invasive hematological prognostic markers for recurrent gliomas treated with bevacizumab.A close relationship emerged between inflammation and angiogenesis.

关键词： Recurrent glioma bevacizumab predictive biomarker inflammatory indices lymphocytes

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：